All In Biotech

Drug Trial Radar · NCT07706530

Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)

A Phase 2 Randomized, Double Blind, Clinical Trial (RCT) to Assess the Efficacy, Safety, and Tolerability of Oral CBP-0276 200mg QD, 800mg QD or Placebo for CBP-0276, Administered to Adults With Active Psoriatic Arthritis (PsA).

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Feb 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Clarent Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks

Conditions

  • Arthritic Psoriasis

Interventions

  • CBP-0276 capsules 100mgDrug

    capsule with CBP-0276 powder

  • PlaceboDrug

    Capsule with placebo for CBP-0276

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change on severity of symptoms at lest 20% at week 24Time frame: week 24 after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Innovacion y Desarrollo en Ciencias de la Salud (IDeCSa)

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.